Challenging antimicrobial susceptibility and evolution of resistance (OXA-681) during treatment of a Pseudomonas aeruginosa ST175 clone long-term nosocomial infection.

We described the emergence of the novel OXA-681 during treatment of nosocomial infection caused by a ST175 high-risk clone. The ability of OXA-681 to confer cross-resistance to ceftolozane/tazobactam and ceftazidime/avibactam together with the complex antimicrobial resistance profiles exhibited by the clinical strains harbouring this new enzyme argue for maintaining active surveillance on emerging broad-spectrum resistance in P. aeruginosa.
PMID: 31383659 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - August 4, 2019 Category: Microbiology Authors: Arca-Suárez J, Fraile-Ribot P, Vázquez-Ucha JC, Cabot G, Martínez-Guitián M, Lence E, González-Bello C, Beceiro A, Rodríguez-Iglesias M, Galán-Sánchez F, Bou G, Oliver A Tags: Antimicrob Agents Chemother Source Type: research